The in vitro effects of Pseudomonas aeruginosa elastase (P. aeruginosa E) and of human leukocyte elastase on human airway lysozyme (HAL) were investigated. P. aeruginosa E inactivated and cleaved HAL, whereas human leukocyte elastase had no effect. Total inactivation of HAL by P. aeruginosa E was observed after 120 min of incubation at 37°C, for an elastase-to-lysozyme molar ratio of 1:5. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of reaction mixtures containing HAL and P. aeruginosa E in an elastase-to-lysozyme molar ratio of 1:10 showed a progressive disappearance of the HAL band upon increasing the incubation time with P. aeruginosa E. Gel filtration chromatography indicated that HAL was cleaved into at least three peptide fragments. The cleavage of HAL by P. aeruginosa E was accompanied by parallel losses of its bacteriolytic activity and its immunoreactive property.
Lysozyme is an enzyme present in high concentration in airway secretions from patients with chronic pulmonary diseases (3, 25) . Surface epithelium, human submucosal tracheal glands, and pulmonary alveolar macrophages are the major contributors for most of the lysozyme found in vivo in human airway secretions (24) . Human monocytes and leukocytes have been shown to contain lysozyme (12, 23) . The physiological role of human lysozyme remains unclear, and several functions have been reported in recent years. Because of its bacteriological activity (muramidase activity) on cell walls of sensitive microorganisms such as Micrococcus luteus (35) and some strains of staphylococci or streptococci (8) , lysozyme is generally considered as an antibacterial agent implicated in the local pulmonary defense mechanisms. However, it has been suggested that most pathogenic bacteria are insensitive to lysozyme in the absence of antibodies, complement, or other enzymes (10, 40) . The possible role of human airway lysozyme (HAL) in controlling the rheological properties of airway secretions has also been suggested. According to Jenssen et al. (18) , the interaction between positive charges of lysozyme and negative charges of acidic mucins may be responsible for building up a macromolecule network, giving mucuses their gel-like properties which are necessary for efficient mucociliary transport (36) . In a recent study, Gordon et al. (11) postulate that human lysozyme may also function in a negative feedback system to modulate the inflammatory response. They reported that in vitro lysozyme from urine origin inhibited the leukocyte chemotactic motility and the production of toxic oxygen radicals by stimulated leukocytes.
In purulent and infected bronchial secretions, proteolytic enzymes are released from bacteria and leukocytes (6, 39) . These proteases are able to degrade and inactivate some proteins implicated in the defense of lungs against invading bacteria. For example, Pseudomonas aeruginosa, a pathogen that often causes very severe lung infections (4, 15) secretes an elastase which can inactivate immunoglobulin G antibodies (7), several human complement factors (37) , and * Corresponding author.
the two major inhibitors of serine proteinases present in lungs, the alpha 1 proteinase inhibitor (33) and the bronchial inhibitor (20) . An in vitro study (5) showed that P. aeruginosa elastase (P. aeruginosa E) was also able to cleave human immunoglobulin A and secretory immunoglobulin A, the latter being considered as the major immunoglobulin of the respiratory tract. The elastase released by human leukocytes has also been shown to degrade in vitro human immunoglobulins (9) and the C3 and C5 component of human complement (21) . Therefore, during in vivo infection with purulent airway secretions, the increased concentration of proteolytic enzymes released from bacteria and leukocytes should induce an irreversible degradation or inactivation (or both) of locally produced proteins, such as lysozyme, which are potentially important in the lung microbial defense. Such a situation may be commonly encountered in patients with cystic fibrosis, which is a genetic disease characterized by the colonization of the airways with P. aeruginosa (14, 26) .
The purpose of the present work was to examine the in vitro effects of P. aeruginosa E and human leukocyte elastase (HLE) on the bacteriolytic activity and molecular properties of lysozyme isolated from human airway secretions. (22), and we estimated an apparent molecular weight of 15,000 for HAL. The specific activity of HAL was about 3.1 times higher than that of the hen egg-white lysozyme (Sigma Chemical Co., St. Louis, Mo.).
MATERIALS
HLE was prepared from purulent sputum samples according to the method of Martodam et al. (29) . The purification procedure involved NaCl extraction, affinity chromatography on Sepharose-bound Trasylol, and ion exchange chromatography on CM Sephadex C50 (Pharmacia). The enzyme was pure as judged by polyacrylamide gel electrophoresis at pH 4.0, and 98% was active, based on active site titration using turkey ovomucoid (42) .
Crystalline P. aeruginosa elastase was supplied by Nagase Biochemicals Ltd., Tokyo, Japan. The molar concentrations of HAL, HLE and P. aeruginosa E were calculated by using molecular weights of 15,000, 29,000 (1), and 23,000 (32) (Fig. 1) . The Proteolysis. To determine whether the inactivation of HAL by P. aeruginosa E occurred by proteolysis, incubation mixtures with a P. aeruginosa E-to-HAL molar concentration ratio of 1:10 were analyzed by SDS-polyacrylamide gel electrophoresis and by gel filtration chromatography. Gel electrophoresis patterns ( Fig. 2A) indicate that the band corresponding to HAL progressively disappeared during incubation with P. aeruginosa E. After 180 min of incubation ( Fig. 2A, lane 6) , no material remained at the undegraded HAL position. The gel slabs were scanned and the relative amount of the remaining HAL band was plotted versus the corresponding HAL lytic activity. As seen in Fig.  2B , the degradation of HAL strongly correlated with the loss of its lytic activity (r = 0.99, P < 0.001). The effect of incubation time on the cleavage of HAL by P. aeruginosa E was further analyzed by gel filtration chromatography on Ultrogel AcA 202. The elution profiles of incubation mixtures containing P. aeruginosa E and HAL in an elastaseto-lysozyme molar concentration ratio of 1:10 showed that HAL was progressively cleaved into several lower molecular weight fragments (Fig. 3) . After 180 min of incubation, which corresponded to a 100% inactivation of HAL lytic activity, the elution profile showed at least three major peak areas of peptide fragments detected at 280 nm.
Immunoreactivity. The effect of incubation time on the cleavage of HAL by P. aeruginosa E in a P. aeruginosa E-to-HAL molar concentration ratio of 1:10 was also studied by rocket immunoelectrophoresis (Fig. 4) . It appeared that the surface of HAL immunoprecipitate decreased with the duration of incubation with P. aeruginosa E. After 60 min of incubation, the surface of HAL immunoprecipitate was 60% less than that of the control. After 120 min of incubation, no HAL immunoprecipitate was observed. Similar to gel electrophoresis patterns, the loss in the immunoreactive property of HAL correlated strongly with the loss of its lytic activity (r = 0.99, P < 0.001). DISCUSSION High concentrations of leukocyte elastase have been observed in infected bronchial secretions from chronic bronchitis (39) and cystic fibrosis patients (41) . P. aeruginosa, a dominant pathogen often isolated in sputa from cystic fibrosis patients (14, 26) , is well known to produce extracellular proteases such as alkaline protease and elastase (30, 31, 34) . The latter is considered as an important virulence factor (2) involved in the pathogenesis of P. aeruginosa infections (32, 43) . However, the interaction of the elastases released by leukocytes and P. aeruginosa with HAL has still not been investigated. The present work is, to our knowledge, the first to demonstrate clearly that P. aeruginosa E markedly inactivates HAL in vitro. On the other hand, it is surprising that HLE which has been shown to degrade human immunoglobulins (9) and complement components in vitro (21) , has no effect on HAL lytic activity, even in a high concentration of HLE (1:1 molar ratio).
The loss of HAL functional activity by P. aeruginosa E is accompanied by proteolytic cleavage of HAL. Inactivation and breakdown of HAL were demonstrated both by functional assays (Fig. 1) and by polyacrylamide gel electrophoresis, gel filtration chromatography and rocket immunoelectrophoresis, using specific human lysozyme antiserum (Fig.  2, 3, and 4) . The degraded fragments of HAL were not observed on polyacrylamide gels at 15% acrylamide concentration, suggesting that P. aeruginosa E had degraded HAL into low-molecular-weight polypeptides not detected by the gel system used. On the other hand, these degraded products have been detected by gel filtration chromatography on Ultrogel AcA 202, showing and confirming that P. aeruginosa E cleaved HAL into low-molecular-weight fragments in a time-dependent reaction (Fig. 3) . Additional studies are under consideration to characterize these peptide fragments and the sites of the HAL molecule susceptible to hydrolysis by P. aeruginosa E.
According to our in vitro findings, we suggest that HAL might be inactivated and degraded in P. aeruginosa-infected bronchial secretions. However, we have recently shown (17) that there is no significant difference in immunological concentrations of HAL in cystic fibrosis sputa regardless of their P. aeruginosa numeration. This may be due to either a HAL release secondary to an increased granulocyte turnover observed in chronic bacterial infection of the respiratory tract (16) or to an inactivation of P. aeruginosa E. Recently, Doring et al. (6) have suggested that specific antibodies to P. aeruginosa E might neutralize the proteolytic activity of this elastase in vivo. According to these authors, P. aeruginosa E was only detected in bronchial secretions from cystic fibrosis patients when antibodies to this elastase were lacking in sera and bronchial secretions. It has also been demonstrated that plasma alpha-2 macroglobulin completely inhibits P. aeruginosa E (13) . In a recent study, Tournier et al. (41) suggest that alpha-2 macroglobulin may also be a potential factor limiting P. aeruginosa E activity in vivo in cystic fibrosis bronchial secretions. They showed that alpha-2 macroglobulin concentrations were negatively correlated with P. aeruginosa E activities in sputa from cystic fibrosis patients which were contaminated by P. aeruginosa. These results suggest that P. aeruginosa E-induced inactivation of HAL may be restricted in vivo by specific antibodies to P. aeruginosa E or alpha-2 macroglobulin or both.
In summary, the present work demonstrates that HAL is cleaved and inactivated by P. aeruginosa E and not by HLE in vitro. Further studies should be undertaken to investigate whether P. aeruginosa E may actually degrade HAL in vivo and therefore limit its potential antibacterial role in defense of the lung.
